ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Tuesday, November 9, 2021

3:45PM-4:00PM: Abstract Number: 1928

In Vitro and In Vivo Evidence for DOCK8 as a Risk Allele for Cytokine Storm Syndrome, Including COVID-19 and MIS-C

Abstracts: Pediatric Rheumatology – Basic Science (1927–1930)

3:45PM-4:00PM: Abstract Number: 1924

Patient Clustering Based on Multimorbidity Patterns Predicts Healthcare Utilization and Mortality in Rheumatoid Arthritis Within Independent Real-World Datasets

Abstracts: Epidemiology & Public Health II: Inflammatory Arthritis (1923–1926)

4:00PM-4:15PM: Abstract Number: 1933

Association Between Race/Ethnicity and COVID-19 Outcomes in Systemic Lupus Erythematosus (SLE) in United States Patients: Data from the COVID-19 Global Rheumatology Alliance

Abstracts: SLE – Diagnosis, Manifestations, & Outcomes II: Predictors & Longitudinal Outcomes (1931–1934)

4:00PM-4:15PM: Abstract Number: 1929

Metabolomics Identifies Early Mechanisms of Atherogenic Dyslipidaemia in Juvenile-SLE Patients Associated with Inflammation

Abstracts: Pediatric Rheumatology – Basic Science (1927–1930)

4:00PM-4:15PM: Abstract Number: 1943

Post-inflammatory and Degenerative Changes in Patients with Psoriatic Arthritis and Axial Manifestations: Post-hoc Analysis from a Double-blind, Randomized, Phase 3b Trial

Abstracts: Spondyloarthritis Including PsA – Treatment II: Biologic Therapies (1943–1946)

4:00PM-4:15PM: Abstract Number: 1939

Risk of Cardiovascular Outcomes in Patients Treated with Tofacitinib: First Results from the Safety of TofAcitinib in Routine Care Patients with Rheumatoid Arthritis (STAR-RA) Study

Abstracts: RA – Treatments I: Safety & Harms (1939–1942)

4:00PM-4:15PM: Abstract Number: 1925

Risk of Heart Failure in Patients with Inflammatory Disease: A Population-Based Study

Abstracts: Epidemiology & Public Health II: Inflammatory Arthritis (1923–1926)

4:00PM-4:15PM: Abstract Number: 1935

Skewed Escape from X-inactivation: Insights into the Female Bias of Sjögren’s Syndrome

Abstracts: Genetics, Genomics & Proteomics (1935–1938)

4:15PM-4:30PM: Abstract Number: 1936

A Neutrophil Degranulation Signature Identifies Proliferative Lupus Nephritis

Abstracts: Genetics, Genomics & Proteomics (1935–1938)

4:15PM-4:30PM: Abstract Number: 1926

Effectiveness of the Making It Work™ Program at Improving Absenteeism in Workers with Inflammatory Arthritis – Results of a Randomized Controlled Trial

Abstracts: Epidemiology & Public Health II: Inflammatory Arthritis (1923–1926)

4:15PM-4:30PM: Abstract Number: 1934

Intra-Individual Change in Cognitive Function Among Adults with Systemic Lupus Erythematosus: A Markov Analysis over 7 Years

Abstracts: SLE – Diagnosis, Manifestations, & Outcomes II: Predictors & Longitudinal Outcomes (1931–1934)

4:15PM-4:30PM: Abstract Number: 1940

Malignancies in Patients Aged ≥ 50 Years with RA and ≥ 1 Additional Cardiovascular Risk Factor: Results from a Phase 3b/4 Randomized Safety Study of Tofacitinib vs TNF Inhibitors

Abstracts: RA – Treatments I: Safety & Harms (1939–1942)

4:15PM-4:30PM: Abstract Number: 1930

Single-Cell Genomics Reveals a Shared Monocyte Interferon Program in a Subset of Patients with Systemic Juvenile Idiopathic Arthritis, Macrophage Activation Syndrome and Lung Disease

Abstracts: Pediatric Rheumatology – Basic Science (1927–1930)

4:15PM-4:30PM: Abstract Number: 1944

Sustained Remission/Low Disease Activity Is Feasible in the Long Term in Patients with Psoriatic Arthritis Treated with IL-23/12 Inhibition with Ustekinumab (STELARA®) and Tumor Necrosis Factor Inhibitors in a Real-World, Multicenter Study

Abstracts: Spondyloarthritis Including PsA – Treatment II: Biologic Therapies (1943–1946)

4:30PM-4:45PM: Abstract Number: 1945

Efficacy of Upadacitinib on Psoriatic Arthritis with Axial Involvement Defined by Investigator Assessment and PRO-Based Criteria: Results from Two Phase 3 Studies

Abstracts: Spondyloarthritis Including PsA – Treatment II: Biologic Therapies (1943–1946)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].